Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 909 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR ESMO Manifesto – Translating Scientific Evidence Into Effective Public Health Policy October 20, 2023 Girls Aloud members to join forces to raise money in Sarah... June 14, 2022 Analysis Patterns of Systemic Anticancer Treatment at End-of-Life Indicates No Changes... November 2, 2022 Dog Showers His Mom with Snuggles and Makes Her Laugh During... December 6, 2021 Load more HOT NEWS Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab... Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer EMA Recommends Granting Marketing Authorisation for Efbemalenograstim Alfa The Largest Randomised Study to Date Points to Low Ipsilateral Breast...
